•
Jun 30, 2024

Invivyd Q2 2024 Earnings Report

Invivyd reported financial results for Q2 2024, launched PEMGARDA commercially with $2.3 million in net product revenue, and achieved Medicare and Medicaid coverage.

Key Takeaways

Invivyd launched PEMGARDA commercially in Q2 2024, generating $2.3 million in net product revenue. The company ended the quarter with $147.9 million in cash and cash equivalents and is preparing for the peak fall/winter respiratory virus season.

PEMGARDA launched commercially in Q2 2024 with $2.3 million of net product revenue.

Commercial results accelerated in early Q3 2024.

New commercial leadership was appointed with Tim Lee as Chief Commercial Officer.

Cash and cash equivalents totaled $147.9 million at the end of Q2 2024.

Total Revenue
$2.26M
0
EPS
-$0.4
Previous year: -$0.46
-13.0%
Gross Profit
$2.18M
Cash and Equivalents
$148M
Previous year: $122M
+21.3%
Free Cash Flow
-$41.6M
Previous year: -$37.4M
+11.3%
Total Assets
$177M
Previous year: $315M
-43.8%

Invivyd

Invivyd

Invivyd Revenue by Segment

Forward Guidance

Invivyd anticipates 2024 net product revenue of $150 million to $200 million and expects to end 2024 with at least $75 million in cash and cash equivalents, based on current operating plans and recent resource realignment.